Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
After finishing at $2.74 in the prior trading day, Clover Health Investments Corp (NASDAQ: CLOV) closed at $2.79, up 1.82%. In other words, the price has increased by $1.82 from its previous closing price. On the day, 6.47 million shares were traded. CLOV stock price reached its highest trading level at $2.795 during the session, while it also had its lowest trading level at $2.74.
Ratios:
Our goal is to gain a better understanding of CLOV by taking a closer look at its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on December 17, 2024, initiated with a Buy rating and assigned the stock a target price of $6.
On October 07, 2024, UBS started tracking the stock assigning a Neutral rating and target price of $4.
Cowen Upgraded its Underperform to Market Perform on February 02, 2022, whereas the target price for the stock was revised from $7 to $3.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 17 ’25 when Reynoso Jamie L. sold 20,450 shares for $2.86 per share. The transaction valued at 58,487 led to the insider holds 3,196,401 shares of the business.
JAMIE REYNOSO bought 20,450 shares of CLOV for $59,714 on Jun 17 ’25. On Mar 07 ’25, another insider, Edwards Carladenise Armbrister, who serves as the Director of the company, sold 200,000 shares for $3.61 each. As a result, the insider received 722,000 and left with 273,227 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLOV now has a Market Capitalization of 1394430848 and an Enterprise Value of 1259782272. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.96 while its Price-to-Book (P/B) ratio in mrq is 3.99. Its current Enterprise Value per Revenue stands at 0.847 whereas that against EBITDA is -54.998.
Stock Price History:
The Beta on a monthly basis for CLOV is 1.90, which has changed by 1.2682927 over the last 52 weeks, in comparison to a change of 0.12463009 over the same period for the S&P500. Over the past 52 weeks, CLOV has reached a high of $4.87, while it has fallen to a 52-week low of $1.18. The 50-Day Moving Average of the stock is -14.38%, while the 200-Day Moving Average is calculated to be -21.82%.
Shares Statistics:
The stock has traded on average 6.14M shares per day over the past 3-months and 7732330 shares per day over the last 10 days, according to various share statistics. A total of 388.51M shares are outstanding, with a floating share count of 382.25M. Insiders hold about 24.89% of the company’s shares, while institutions hold 20.90% stake in the company. Shares short for CLOV as of 1749772800 were 22280296 with a Short Ratio of 3.63, compared to 1747267200 on 15577657. Therefore, it implies a Short% of Shares Outstanding of 22280296 and a Short% of Float of 5.5.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
